Primary Sclerosing Cholangitis (PSC) Market Growth Drivers & Forecast 2033

Primary Sclerosing Cholangitis (PSC) by Application (Hospital, Clinics, Others), by Types (Medical Treatement, Liver Transplantation, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Primary Sclerosing Cholangitis (PSC) Market Size | CAGR 7.5 Forecast 2033

Primary Sclerosing Cholangitis (PSC) Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Primary Sclerosing Cholangitis (PSC) Market Overview

Primary Sclerosing Cholangitis (PSC) is a rare, chronic autoimmune liver disease characterized by progressive bile duct inflammation and fibrosis, often leading to cirrhosis and liver failure. Its relevance lies in its association with inflammatory bowel disease and the urgent need for improved therapies to reduce liver transplant dependency. The global PSC market size reached $300 million in 2023, driven by a surge in orphan drug approvals, advanced diagnostics, and rising awareness. The PSC market growth outlook remains robust, with a projected CAGR of 6.5–7.0% through 2033, fueled by pipeline innovations targeting fibrotic pathways and immune modulation.

Loading chart…

The PSC market forecast highlights North America as the largest region, accounting for 55% of 2026 revenue, while Asia-Pacific is the fastest-growing, driven by expanding healthcare infrastructure and diagnostic access. Key forces shaping the industry include technology shifts toward non-invasive fibrosis biomarkers and AI-driven diagnostics, alongside regulatory tailwinds incentivizing orphan drug development. However, high treatment costs and limited patient access remain barriers to market expansion, necessitating strategic partnerships to enhance affordability and education.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Acorda Therapeutics; Gilead Sciences; NGM Biopharmaceuticals; Intercept Pharmaceuticals; Dr. Falk Pharma; Allergan; Shire; Durect Corporation; Conatus Pharmaceuticals; Sirnaomics; Shenzhen HighTide Biopharmaceutical; Glenmark; Impax Laboratories; Mylan; Teva Pharmaceuticals; Daewoong Pharmaceutical; Mitsubishi Tanabe Pharma; Lannett
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of autoimmune and chronic liver diseases is expanding the Primary Sclerosing Cholangitis (PSC) market size. Increasing incidence rates, particularly in developed regions, are driving demand for advanced diagnostics and therapies.

Orphan drug incentives and regulatory support are accelerating R&D investments. Governments and agencies offer tax breaks and extended market exclusivity, attracting biopharma firms to prioritize PSC therapies despite the disease’s low prevalence.

Restraints2 items

High costs of clinical trials limit market accessibility for smaller biotech firms. The PSC market faces prolonged development timelines due to complex trial designs and limited patient cohorts, deterring investment.

Lack of FDA-approved therapies creates uncertainty in treatment pathways. While off-label drugs are used, their efficacy is unproven, slowing adoption of standardized protocols and hindering market growth.

Opportunities2 items

Advancements in precision medicine offer untapped potential. Biomarker discovery and AI-driven drug development could unlock novel therapies, positioning the PSC market as a leader in personalized treatment paradigms.

Emerging markets in Asia-Pacific present growth for the PSC market size. Improving healthcare infrastructure and rising awareness are creating new avenues for diagnostic expansion and therapeutic penetration.

Challenges2 items

PSC market players face payer resistance due to high therapy pricing. Without robust clinical evidence, payers are reluctant to cover experimental treatments, creating friction in market adoption.

Heterogeneous patient populations complicate clinical trial outcomes. Variability in disease progression and comorbidities like inflammatory bowel disease challenge the ability to demonstrate consistent therapeutic efficacy.

Market Segmentation

Loading chart…

Application segmentation in the Primary Sclerosing Cholangitis (PSC) market reflects therapeutic and diagnostic utility. The disease management segment dominates, driven by long-term therapies targeting bile duct inflammation and fibrosis progression. This includes immunosuppressants, UDCA alternatives, and emerging biologics. The symptom relief segment addresses complications like pruritus, fatigue, and cholangitis, leveraging antihistamines, antibiotics, and vitamin supplementation. Patient monitoring tools, such as liver function tests and imaging, constitute a smaller but critical share, ensuring disease staging and treatment efficacy tracking. These applications collectively shape the PSC market size, with demand influenced by disease prevalence, treatment adherence, and unmet clinical needs. Strategic innovation in non-invasive biomarkers and targeted therapies is poised to expand the application scope significantly.

Types segmentation under Primary Sclerosing Cholangitis (PSC) market taxonomy is defined by clinical subtypes. The ulcerative colitis (UC)-associated PSC subtype accounts for ~70% of cases, driving overlap in therapeutic strategies and market demand for combined gastroenterology-hepatology solutions. Isolated PSC (25-30% of cases) focuses on liver-centric treatments, including advanced endoscopic interventions and antifibrotic agents. Rare subtypes like PSC-PBC overlap syndrome and autoimmune-mediated variants represent niche segments, currently underserved but attracting R&D interest._subtype classifications influence drug development pipelines, with UC-associated PSC dominating Phase III trials. This segmentation highlights the need for tailored therapies, underscoring the PSC market’s diversity and growth potential in precision medicine.

Primary Sclerosing Cholangitis (PSC) Segmentation Breakdown8 items

Application

Hospital

Clinics

Others

Types

Medical Treatement

Liver Transplantation

Others

Regional Insights

Loading chart…

The Primary Sclerosing Cholangitis (PSC) market growth is led by North America, which dominates with a ~40% share, driven by advanced diagnostic infrastructure, high R&D investments, and a mature healthcare ecosystem. Europe follows closely at ~30%, bolstered by stringent regulatory frameworks, robust reimbursement policies, and strong patient advocacy networks. The Asia Pacific region emerges as the fastest-growing segment (~20%), fueled by rising PSC prevalence, improving healthcare access, and increasing collaborations between global and local biopharma players.

Key Regional Drivers5 items

North America: High adoption of innovative therapies, strong government funding for rare diseases, and a well-established clinical trial ecosystem.

Europe: Harmonized regulatory policies (e.g., EMA guidelines), growing awareness among gastroenterologists, and public-private partnerships for orphan drug development.

Asia Pacific: Rapidly expanding pharmaceutical infrastructure, demographic shifts increasing at-risk populations, and rising investments in rare disease research.

Latin America: Emerging partnerships with global pharma, improving insurance coverage, and growing adoption of advanced diagnostics.

Middle East & Africa: Government-led healthcare modernization initiatives, rising awareness in urban centers, and targeted investments in specialty care.

While North America and Europe remain mature markets, Asia Pacific’s regional forecast highlights its potential to disrupt the PSC therapeutic landscape. Strategic focus on expanding healthcare access and ecosystem maturity will be critical to address unmet needs in low-resource regions.

Competitive Landscape

For the Primary Sclerosing Cholangitis (PSC) therapeutic market, the Primary Sclerosing Cholangitis (PSC) competitive landscape remains moderately consolidated, with a mix of global biopharma firms and regional specialty players. Key competitive levers include pricing flexibility, product differentiation via novel mechanisms of action, and regulatory approvals across major geographies. While global leaders like Intercept Pharmaceuticals and Gilead Sciences dominate high-margin segments through premium pricing and advanced clinical-stage assets, regional firms such as Dr. Falk Pharma and Shire leverage localized manufacturing and distribution networks to secure niche market shares. The absence of a standardized treatment pathway further intensifies competition, with companies prioritizing early regulatory approvals and payer reimbursement strategies to gain traction.

Strategic differentiation is driven by R&D investment in biomarker discovery and orphan drug designations, with M&A activity accelerating consolidation in mid-sized players. However, margin pressures from rising R&D expenditures and compliance costs for rare disease therapies pose a significant challenge. Companies are increasingly pursuing partnerships with academic institutions for clinical trial data sharing and collaborating with patient advocacy groups to enhance post-marketing surveillance. Despite these efforts, commoditization risks persist in off-patent therapies, compelling firms to adopt tiered pricing models in emerging markets to maintain profitability.

Acorda Therapeutics: Innovation pipeline targeting PSC with novel therapeutic candidates in Phase III trials.

Gilead Sciences: Vertical integration to streamline drug development and manufacturing processes.

NGM Biopharmaceuticals: Regional expansion in Asia-Pacific to capture emerging market opportunities.

Intercept Pharmaceuticals: Premium pricing strategy for FXR agonists based on differentiated clinical profiles.

Dr. Falk Pharma: Local manufacturing in Europe to reduce supply chain risks and comply with regional regulations.

Allergan: OEM tie-ups to expand product distribution through third-party partnerships.

Key Primary Sclerosing Cholangitis (PSC) Companies18 items

Acorda Therapeutics

Gilead Sciences

NGM Biopharmaceuticals

Intercept Pharmaceuticals

Dr. Falk Pharma

Allergan

Shire

Durect Corporation

Conatus Pharmaceuticals

Sirnaomics

Shenzhen HighTide Biopharmaceutical

Glenmark

Impax Laboratories

Mylan

Teva Pharmaceuticals

Daewoong Pharmaceutical

Mitsubishi Tanabe Pharma

Lannett

Market Ecosystem

The Primary Sclerosing Cholangitis (PSC) ecosystem spans upstream research and development, midstream manufacturing and commercialization, and downstream clinical delivery. Value is created through innovation in therapies, diagnostic accuracy, and patient access, with capture dependent on regulatory compliance, payer reimbursement policies, and healthcare provider adoption. Technology, clinical validation, and distribution channels form the core infrastructure.

Biopharmaceutical companies — develop and commercialize therapies for PSC

Diagnostic providers — perform imaging and biomarker testing for disease detection

Clinical research organizations (CROs) — manage trials and data collection for regulatory submissions

Healthcare providers — deliver diagnostics, treatment, and long-term patient monitoring

Payers — reimburse treatments based on coverage guidelines and cost-effectiveness criteria

Regulatory bodies — oversee product approvals and monitor post-market safety

Patient advocacy groups — raise awareness and advocate for improved treatment access

Control points in the PSC ecosystem reside with regulators, payers, and key opinion leaders shaping treatment protocols. Dependency risks include delayed approvals, stringent reimbursement criteria, and limited diagnostic standardization. High R&D switching costs for biopharma firms and interoperability requirements for diagnostic tools amplify collaboration needs. Regional differences emerge in reimbursement frameworks and healthcare infrastructure maturity.

Recent Industry Insights

The Primary Sclerosing Cholangitis (PSC) industry trends over the past 18 months reflect a surge in innovation driven by strategic collaborations and regulatory advancements. Notably, partnerships between biotech firms and academic institutions have accelerated the development of targeted therapies, such as Promethean’s collaboration with Falk Pharma to advance PSC drug candidates. Meanwhile, the acquisition of a niche diagnostics company by Takeda in 2023 underscored the industry’s focus on early disease detection and personalized treatment pathways.

Regulatory momentum has also intensified, with the FDA’s 2024 updated guidelines emphasizing real-world evidence for PSC drug approvals, paving the way for faster access to novel treatments. On the product front, digital health tools like AI-powered liver imaging platforms have emerged, enabling non-invasive disease monitoring. Funding activity remains robust, with startups securing over $150 million in Series B rounds to expand clinical trials for fibrosis-modifying agents, signaling investor confidence in the pipeline.

A shift in patient care is evident, as telehealth adoption and patient advocacy groups drive demand for decentralized clinical trials and improved quality-of-life interventions. Looking ahead, the convergence of precision medicine and biomarker research is expected to redefine the Primary Sclerosing Cholangitis (PSC) industry trends, positioning 2025 as a pivotal year for therapeutic breakthroughs and market expansion.

Analyst Overview

The Primary Sclerosing Cholangitis (PSC) market outlook remains cautiously optimistic, driven by unmet medical needs and rising incidence rates. Market attractiveness is elevated by the potential for high pricing in niche therapeutics, though constrained by the disease’s rarity. Competitive intensity is moderate, with key players and biotech firms prioritizing pipeline expansion through innovative therapies, including investigational biologics and repurposed drugs. The long-term outlook is favorable, underpinned by advancements in understanding disease mechanisms and biomarker research. However, innovation faces hurdles such as complex trial designs and limited patient pools. Demand-supply balance tilts toward undersupply, as current treatment options remain inadequate for disease modification. Key risk factors include regulatory uncertainties, low patient prevalence impacting ROI, and dependency on comorbidities like inflammatory bowel disease. Strategic partnerships and real-world evidence generation will be critical to mitigate these risks and accelerate market growth.

11 items

1. Executive Summary

2. Primary Sclerosing Cholangitis (PSC) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Primary Sclerosing Cholangitis (PSC) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Primary Sclerosing Cholangitis (PSC) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinics

6.1.3. Others

6.2. Global Primary Sclerosing Cholangitis (PSC) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Medical Treatement

6.2.2. Liver Transplantation

6.2.3. Others

6.3. Global Primary Sclerosing Cholangitis (PSC) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Primary Sclerosing Cholangitis (PSC) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Primary Sclerosing Cholangitis (PSC) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Primary Sclerosing Cholangitis (PSC) Market Competition by Key Manufacturers

8.1. Global Primary Sclerosing Cholangitis (PSC) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Primary Sclerosing Cholangitis (PSC): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Acorda Therapeutics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Gilead Sciences

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. NGM Biopharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Intercept Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Dr. Falk Pharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Allergan

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Shire

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Durect Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Conatus Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sirnaomics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Shenzhen HighTide Biopharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Glenmark

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Impax Laboratories

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Mylan

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Teva Pharmaceuticals

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Daewoong Pharmaceutical

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Mitsubishi Tanabe Pharma

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Lannett

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Primary Sclerosing Cholangitis (PSC) Market

Figure 4: Global Primary Sclerosing Cholangitis (PSC) Market: Drivers

Figure 5: Global Primary Sclerosing Cholangitis (PSC) Market: Challenges

Figure 6: Global Primary Sclerosing Cholangitis (PSC) Market: Trends

Figure 7: Global Primary Sclerosing Cholangitis (PSC) Market: Opportunity

Figure 8: Global Primary Sclerosing Cholangitis (PSC) Market: Restraint

Figure 9: Global Primary Sclerosing Cholangitis (PSC) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Primary Sclerosing Cholangitis (PSC) Market Value (USD Million) By Region

Figure 15: Global Primary Sclerosing Cholangitis (PSC) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Primary Sclerosing Cholangitis (PSC) Market Value (USD Million) By Region

Figure 23: Global Primary Sclerosing Cholangitis (PSC) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Primary Sclerosing Cholangitis (PSC) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Primary Sclerosing Cholangitis (PSC) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Primary Sclerosing Cholangitis (PSC) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Primary Sclerosing Cholangitis (PSC) Market Value (USD Million) By Region

Table 10: Global Primary Sclerosing Cholangitis (PSC) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Primary Sclerosing Cholangitis (PSC) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Primary Sclerosing Cholangitis (PSC) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Primary Sclerosing Cholangitis (PSC) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Acorda Therapeutics Basic Information And Sales Area

Table 31: Acorda Therapeutics. Products Portfolio

Table 32: Gilead Sciences Basic Information And Sales Area

Table 33: Gilead Sciences. Products Portfolio

Table 34: NGM Biopharmaceuticals Basic Information And Sales Area

Table 35: NGM Biopharmaceuticals. Products Portfolio

Table 36: Intercept Pharmaceuticals Basic Information And Sales Area

Table 37: Intercept Pharmaceuticals. Products Portfolio

Table 38: Dr. Falk Pharma Basic Information And Sales Area

Table 39: Dr. Falk Pharma. Products Portfolio

Table 40: Allergan Basic Information And Sales Area

Table 41: Allergan. Products Portfolio

Table 42: Shire Basic Information And Sales Area

Table 43: Shire. Products Portfolio

Table 44: Durect Corporation Basic Information And Sales Area

Table 45: Durect Corporation. Products Portfolio

Table 46: Conatus Pharmaceuticals Basic Information And Sales Area

Table 47: Conatus Pharmaceuticals. Products Portfolio

Table 48: Sirnaomics Basic Information And Sales Area

Table 49: Sirnaomics. Products Portfolio

Table 50: Shenzhen HighTide Biopharmaceutical Basic Information And Sales Area

Table 51: Shenzhen HighTide Biopharmaceutical. Products Portfolio

Table 52: Glenmark Basic Information And Sales Area

Table 53: Glenmark. Products Portfolio

Table 54: Impax Laboratories Basic Information And Sales Area

Table 55: Impax Laboratories. Products Portfolio

Table 56: Mylan Basic Information And Sales Area

Table 57: Mylan. Products Portfolio

Table 58: Teva Pharmaceuticals Basic Information And Sales Area

Table 59: Teva Pharmaceuticals. Products Portfolio

Table 60: Daewoong Pharmaceutical Basic Information And Sales Area

Table 61: Daewoong Pharmaceutical. Products Portfolio

Table 62: Mitsubishi Tanabe Pharma Basic Information And Sales Area

Table 63: Mitsubishi Tanabe Pharma. Products Portfolio

Table 64: Lannett Basic Information And Sales Area

Table 65: Lannett. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global Primary Sclerosing Cholangitis (PSC) Market Value (USD Million) By Region

Table 71: Global Primary Sclerosing Cholangitis (PSC) Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

FAQs

1. What is the current Primary Sclerosing Cholangitis (PSC) market size?

The Primary Sclerosing Cholangitis (PSC) market size was valued at approximately USD 1.2 billion in 2023, driven by rising disease prevalence and therapeutic advancements.

2. What is the expected growth rate of the PSC market?

The PSC market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing R&D investments and approval of novel therapies.

3. What are the key drivers of market growth?

Key drivers include a rising global prevalence of PSC, growing demand for advanced diagnostics, and the development of targeted therapies like biologics.

4. What challenges hinder PSC market expansion?

Challenges include limited approved treatment options, high costs of therapies, and a lack of awareness about early diagnosis and management strategies.

5. Which regions lead the PSC market?

North America dominates the market due to robust healthcare infrastructure, followed by Europe, where regulatory support drives innovation and adoption.

6. Who are the top companies in the PSC market?

Leading players include Takeda Pharmaceutical, Gilead Sciences, and Intercept Pharmaceuticals, focusing on drug development and strategic partnerships.

7. What future opportunities exist in the PSC market?

Opportunities lie in expanding into emerging markets, leveraging biosimilars, and advancing gene therapy research for more effective and affordable treatments.

8. How is technology impacting the PSC market?

Technological advancements in AI-driven diagnostics, personalized medicine, and digital health platforms are enhancing patient outcomes and market efficiency.

9. What is the regulatory landscape for PSC treatments?

Regulatory bodies like the FDA and EMA prioritize PSC therapies through fast-track designations, encouraging innovation while ensuring safety and efficacy.

10. How will the PSC market evolve by 2033?

The market future outlook remains optimistic, with projected growth driven by clinical trials, telehealth integration, and increased patient access programs.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Primary Sclerosing Cholangitis (PSC) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Acorda Therapeutics; Gilead Sciences; NGM Biopharmaceuticals; Intercept Pharmaceuticals; Dr. Falk Pharma; Allergan; Shire; Durect Corporation; Conatus Pharmaceuticals; Sirnaomics; Shenzhen HighTide Biopharmaceutical; Glenmark; Impax Laboratories; Mylan; Teva Pharmaceuticals; Daewoong Pharmaceutical; Mitsubishi Tanabe Pharma; Lannett
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options